Partner Headlines - AMGN

  1. Amgen's First Drug For Cardiovascular Disease Gets The Green ...

    GuruFocus
  2. Why Amgen Might Start To Turn Around

    Benzinga
  3. Amgen Has A Big Launch Coming Up

    Benzinga
  4. AMGEN

    IBD
  5. AbbVie Upgraded On $7.8 Billion Imbruvica Potential

    IBD
  6. Short Sellers Come Back To Biotech Stocks

    Benzinga
  7. Making Money With Charles Payne: 02/25/15

    FoxBusiness
  8. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  9. A Look At Dan Loeb's Diversified 13F

    Benzinga
  10. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  11. Short Sellers Retreat From Biotech Stocks

    Benzinga
  12. FDA Advisory Committee To Review Amgen's Talimogene Laherparepvec

    Benzinga
  13. Dan Loeb Offers Mea Culpa For 'Mediocre' Returns

    Benzinga
  14. Dan Loeb Fourth Quarter Investor Letter

    GuruFocus
  15. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  16. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  17. Pfizer Buying Hospira To Inject Growth Into Generics

    IBD
  18. Nuveen's Bob Doll Runs Several Top Funds

    IBD
  19. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  20. Credit Suisse Sees Solid Q4 For Amgen

    Benzinga
  21. Amgen Q4 earnings top views

    IBD
  22. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  23. Making Money With Charles Payne: 01/27/15

    FoxBusiness
  24. Amgen Beats Q4 Expectations

    Benzinga
  25. Stocks Weaken Late; Apple Jumps After Hours

    IBD
  26. Earnings Scheduled For January 27, 2015

    Benzinga
  27. 5 Big Biotech Earnings Releases To Watch This Week

    Benzinga
  28. Can CAR-T Therapy Live Up To The Biotech IPO Hype?

    IBD
  29. New Guru Jana Partners' Newest Stock Buys

    GuruFocus
  30. Express Scripts Eyes New Price War: Anti-PCSK9 Drugs

    IBD
  31. Cholesterol Drug Costs Eyed

    IBD
  32. Amgen's Decline May Be Linked To Comments Of Express Script's ...

    Benzinga
  33. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  34. Regeneron rises on drug data

    IBD
  35. Crude Awakening As Energy Squeezes Overall Q4 Profit

    IBD
  36. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  37. Drugs May Be Blockbusters

    IBD
  38. Weekly Review Shows Five Industries Gain In December

    IBD
  39. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  40. Pharmaceutical Companies Amgen and Kite Partner for Cancer Therapy

    GuruFocus
  41. Kite Pharma Gets Stock Price Increase Post Amgen Deal

    IBD
  42. UPDATE: Barclays Initiates Coverage On Amgen

    Benzinga
  43. Amgen, Kite Reach Cell Deal

    IBD
  44. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  45. Morgan Stanley Issues Wave Of Pharma & Medical Device Upgrades, ...

    Benzinga
  46. Kite Pharma Up On Amgen Cancer Parternship

    IBD
  47. Stocks Drop 1% In Rising Volume; Visa Falls 1%

    IBD
  48. Morning Market Losers

    Benzinga
  49. Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm ...

    Benzinga
  50. Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy ...

    Benzinga
  51. Nasdaq, Russell 2000 Join New-High Party; GoPro Up Again

    IBD
  52. Tesla Motors Up On Battery News; Stocks At Record

    IBD
  53. Biotech Stocks Take A Beating, But Find Support

    IBD
  54. Are There Any Winners Left In The Biotech Space?

    Benzinga
  55. Indexes Turn Mixed On Data; Celgene Dives

    IBD
  56. Express Scripts Picks AbbVie HCV Drugs Over Gilead

    IBD
  57. Stocks Struggle To Hold Gains; Alaska Air, Spirit Up

    IBD
  58. Meet 5 Big Tech Stocks Expected To See Profits Surge

    IBD
  59. Amgen Just Crashed 50% In Premarket, Here's How It Looked

    Benzinga
  60. Druckenmiller Adds Healthcare Stocks to Portfolio

    GuruFocus
  61. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  62. How Can Drugmakers Handle New Pricing Pressures?

    IBD
  63. Gilead Sciences Bucks Trend In Biotech Short Interest

    Benzinga
  64. 3 Biotech ETFs Rally On Merger News

    Benzinga
  65. New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec ...

    Benzinga
  66. Hot Drugmakers Build More Labs, Grab Space In Boston

    IBD
  67. Large-Blend Funds Take The Lead For Year-To-Date Total Returns

    Benzinga
  68. A Look At 3 Overbought ETFs

    Benzinga
  69. Big CEOs Are Less Upbeat, But Plan To Hire More

    IBD
  70. Endonovo Therapeutics Receives Final Commissioned Report Recommendations ...

    GuruFocus
  71. Meet 5 Top Drug Stocks That Are Bolting Past Market

    IBD
  72. AMGEN

    IBD
  73. #PreMarket Primer: Tuesday, November 25: Violent Protests In ...

    Benzinga
  74. Dividend Aristocrats In Focus Part 45: AbbVie

    GuruFocus
  75. Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies ...

    Benzinga
  76. #PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates ...

    Benzinga
  77. Merck Drug Works: Vytorin Study Proves Successful

    IBD
  78. Events for the Week of Nov. 17-21, 2014

    Benzinga
  79. Amgen Shares Consolidating Ahead Of More Gains?

    Benzinga
  80. UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New ...

    Benzinga
  81. Amgen And AstraZeneca Announce Positive Results From Second Pivotal ...

    Benzinga
  82. Big Cap 20 Stuffed With Medical Names

    IBD
  83. Markets Mostly Lower As Americans Head To Vote, Oil Continues ...

    Benzinga
  84. AbbVie Beats Q3 Earnings Estimates, Raises Guidance

    IBD
  85. Ebola Vaccine Contenders

    Benzinga
  86. Stocks Trim Losses After Fed Report; Solarwinds Soars

    IBD
  87. UPDATE: Nomura Upgrades Amgen

    Benzinga
  88. Amgen resists pressure to split

    IBD
  89. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus
  90. Amgen Refuses To Split, But Plans Hearten Investors

    IBD
  91. Amgen At All-Time High, Deutsche Bank Ups Price Target

    Benzinga
  92. Stocks Extend Gains As Alibaba, Tesla Rally

    IBD
  93. Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing

    IBD
  94. Amgen Rallies 3% After Announcing Growth And Capital Plans

    Benzinga
  95. Four Biotechs Lead Health Care Stocks In Big Cap 20

    IBD
  96. Amgen Q3 Earnings Beat Estimates; Guidance Mixed

    IBD
  97. Amgen Earnings Clear Views

    IBD
  98. Amgen Beats Q3 Earnings Estimates

    Benzinga
  99. Twitter Off, Amgen, Buffalo Wild Wings Up After Hours

    IBD
  100. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
Trading Center